ReviewBlood2024
Genetic mechanisms underlying tumor microenvironment composition and function in diffuse large B-cell lymphoma.
Review in Blood, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 45 citations in OpenAlex.
- Neoplastic CD3⁺ B cells remodel the DLBCL tumor microenvironment via single-cell and spatial transcriptomics.Cancer biology & therapy · 2026Article
- Low lymphoma macrophage infiltration predicts poor outcomes for R-CHOP- but not Pola-R-CHP-treated patients with DLBCL.Blood neoplasia · 2026Article
- Erianin induces GSDMD-dependent pyroptosis and synergistically enhances doxorubicin efficacy via the PI3K/AKT signaling pathway in diffuse large B-cell lymphoma.Chinese medical journal · 2026Article
- Oncogenic Mutations and Tumor Microenvironment Alterations in Diffuse Large B-Cell Lymphoma With Bulky Disease.Cancer medicine · 2026Article
- Heterogeneity in primary gastrointestinal DLBCL: from clinical management to molecular mechanisms and treatment strategies.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Review
- Matrix Stiffness Regulates Diffuse Large B-Cell Lymphoma (DLBCL) Spheroid Formation in a Tunable 3D Chitosan Hydrogel Model.Gels (Basel, Switzerland) · 2026Article
- Dissecting diffuse large B-cell lymphoma heterogeneity: New insights from a state-specific molecular characterisation.Clinical and translational medicine · 2026Article
- Incidence of B-cell Malignancies in Patients with Lung Cancer Receiving PD-1 Blockade Therapy.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Article
- Molecular Mechanisms of Diffuse Large B-Cell Lymphoma and the Complexities of Tumor Development.Saudi medical journal · 2026Review
- Phase I study of oral azacitidine plus salvage chemotherapy in relapsed/refractory diffuse large B-cell lymphoma.Annals of hematology · 2026Article
- Tumor-derived HMGB2 induces M2-like macrophage polarization via TRIM65-mediated NLRP3 degradation to promote DLBCL progression.Journal for immunotherapy of cancer · 2026Article
- Prognostic model for diffuse large B-cell lymphoma based on an HBV-associated gene signature and immune microenvironment insights.Annals of hematology · 2026Article
- Article
- Review
- Lipid Metabolism Reprogramming in Diffuse Large B-Cell Lymphoma (DLBCL): Mechanisms and Treatment Strategies.Cancers · 2026Review
- Cutaneous diffuse large B-cell lymphoma induces a macrophage immunosuppressive phenotype through IL-10 secretion.Blood advances · 2026Article
- Integrative Multiomics and Single-Cell Profiling Identify TNFRSF1AComputational and structural biotechnology journal · 2026Article
- The neuro-immune axis in cancer: mechanisms of neural regulation of immunity within the tumor microenvironment to promote cancer progression.Frontiers in immunology · 2026Review
- HBx hijacks the miR-19a-3p/BAMBI/TGF-β1 axis to impair the anti-tumour activity of CD4Clinical and translational medicine · 2026Article
- Fatty acid metabolic signature reveals FASN as an immunosuppressive factor in DLBCL tumor microenvironment.Medical oncology (Northwood, London, England) · 2025Article
Corrections and comments
- Commented on by
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
abstractCells in the tumor microenvironment (TME) of diffuse large B-cell lymphoma (DLBCL) show enormous diversity and plasticity, with functions that can range from tumor inhibitory to tumor supportive. The patient's age, immune status, and DLBCL treatments are factors that contribute to the shaping of this TME, but evidence suggests that genetic factors, arising principally in lymphoma cells themselves, are among the most important. Here, we review the current understanding of the role of these genetic drivers of DLBCL in establishing and modulating the lymphoma microenvironment. A better comprehension of the relationship between lymphoma genetic factors and TME biology should lead to better therapeutic interventions, especially immunotherapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.